p53 as a target for anti-cancer immunotherapy

Molecular Medicine Today

Volumn 3, Issue 4, 1997, Pages 160-167

  Chen, Hailei L ^a   Carbone, David P ^b  

^a EMORY UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; INTERLEUKIN 2; ONCOPROTEIN; PROTEIN P53; TUMOR ANTIGEN;

BIOLISTIC TRANSFORMATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; GENE THERAPY; HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031404849     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-4310(97)01003-4     Document Type: Review

References (48)

1. Gross, L. (1943) Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line, Cancer Res. 3, 326-333
2. Sjogren, H.O., Hellstrom, I. and Klein, G. (1961) Resistance of polyoma virus-immunized mice to transplantation of established polyoma tumors, Exp. Cell. Res. 23, 204-208
3. Klein, G. et al. (1960) Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host, Cancer Res. 20, 1561-1572
4. Chen, L. et al. (1992) Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4, Cell 71, 1093-1102
5. Lee, C.T. et al. (1996) Increased immunogenicity of tumors bearing mutant p53 and P1A epitopes after transduction of B7-1 via recombinant adenovirus. Cancer Gene Ther. 3, 238-244
6. Restifo, N.P. et al. (1991) Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response, J. Immunol. 147, 1453-1459
7. Sameshima, Y. et al. (1992) Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma, Oncogene 7, 451-457
8. Ruiz, C.F. et al. (1991) Molecular analysis of MHC-class-I alterations in human tumor cell lines, Int. J. Cancer (Suppl.) 6, 123-130
9. ras) levels in human breast tumors, Invasion Metastasis 12, 210-217
10. 2m gene expression, J. Clin. Invest. 87, 284-292
11. 2 microglobulin abnormalities in human lung and breast cancer, Int. J. Cancer 67, 756-763
12. Doyle, A. et al. (1985) Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer, J. Exp. Med. 161, 1135-1151
13. Chen, H.L. et al. (1996) A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer, Nat. Genet. 13, 210-213
14. Mizoguchi, H. et al. (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice, Science 258, 1795-1798
15. Gabrilovich, D.I., Ciernik, I.F. and Carbone, D.P. (1996) Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts, Cell. Immunol. 170, 101-110
16. Gabrilovich, D.I. et al. (1996) Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors, Cell. Immunol. 170, 111-119
17. Wiedenfeld, E.A. et al. (1994) Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the HLA A*0201 peptide consensus motif, Cancer Res. 54, 1175-1177
18. Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. (1996) Human lung cancer cells endogenously expressing mutant p53 process and present the mutant epitope, and are lysed by mutant-specific CTL, Clin. Cancer Res. 2, 877-882
19. Gabrilovich, D.I. et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells, Nat. Med. 2, 1096-1103
20. Boon, T. and van der Bruggen, P. (1996) Human tumor antigens recognized by T lymphocytes, J. Exp. Med. 183, 725-729
21. Coulie, P.G. et al. (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. U. S. A. 92, 7976-7980
22. INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281-1284
23. Levine, A.J., Momand, J. and Finley, C.A. (1991) The p53 tumor suppressor gene, Nature 351, 453-456
24. Levine, A.J. (1993) The tumor suppressor genes, Annu. Rev. Biochem. 62, 623-651
25. Linzer, D. and Levine, A. (1979) Characterization of a 54 kDa cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells, Cell 17, 43-52
26. Parada, L.F. et al. (1984) Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation, Nature 312, 649-651
27. Finlay, C., Hinds, P. and Levine, A.J. (1989) The p53 protooncogene can act as a suppressor of transformation, Cell 57, 1083-1093
28. Fields, S. and Jang, S. (1990) Presence of a potent transcription activating sequence in the p53 protein, Science 249, 1046-1049
29. Raycroft, L., Wu, H. and Lozano, G. (1990) Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene, Science 249, 1049-1051
30. Unger, T. et al. (1992) p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer, EMBO J. 11, 1383-1390
31. Kastan, M.B., Plunkett, B.S. and Kuerbitz, S.J. (1992) p53 protein is a cell cycle checkpoint following DNA damage, AACR Proc. 33, 169
32. el-Deiry, W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression, Cell 75, 817-825
33. Caron de Fromental, C. and Soussi, T. (1992) TP53 tumor suppressor gene: a model for investigating human mutagenesis, Genes Chromosomes Cancer 4, 1-15
34. Bodner, S.M. et al. (1992) Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation, Oncogene 7, 743-749
35. Roth, J. et al. (1996) p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge, Proc. Natl. Acad. Sci. U. S. A. 93. 4781-4786
36. Houbiers, J.G. et al. (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53, Eur. J. Immunol. 23, 2072-2077
37. Winter, S.F. et al. (1992) Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation, Cancer Res. 52, 4168-4174
38. Crawford, L.V., Pim, D.C. and Bulbrook, R.D. (1982) Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer, Int. J. Cancer 30, 403-408
39. Schlichtholz, B. et al. (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein, Br. J. Cancer 69, 809-816
40. Tilkin, A.F. et al, (1995) Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer, Eur. J. Immunol. 25, 1765-1769
41. Ropke, M., Regner, M. and Claesson, M.H. (1995) T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors, Scand. J. Immunol 42, 98-103
42. Gabrilovich, D.I. et al. (1995) Cytotoxic T-lymphocytes (CTL) specific for mutant p53-peptides in peripheral blood of patients with cancer: support for specific immune intervention, The 9th International Congress of Immunology A3964, American Association of Immunology
43. Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. (1995) Mutant oncopeptide immunization induces CTL specifically lysing tumor cells endogenously expressing the corresponding intact mutant p53, Hybridoma 14, 139-142
44. + T cells, Proc. Natl. Acad. Sci. U. S. A. 91, 3171-3175
45. Gabrilovich, D.I., Cunningham, HT. and Carbone, D.P. (1997) IL-12 and mutant p53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer, J. Immunother. 19, 414-418
46. Tang, D., DeVit, M. and Johnston, S.A. (1992) Genetic immunization: a simple method for eliciting an immune response, Nature 356, 152-154
47. Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. (1996) Induction of cytotoxic T lymphocytes and anti-tumor immunity with DNA vaccines expressing single T cell epitopes, J. Immunol 156, 2369-2375
48. Dranoff, G. et al (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity, Proc. Natl. Acad. Sci. U. S. A. 90, 3539-3543